Carrero JJ, et al. - In “real-world” patients with myocardial infarction (MI), researchers focused on the burden, predictors, and outcomes related to elevated high-sensitivity C-reactive protein (hsCRP) in this study, which included all-coming MI survivors undergoing hsCRP testing > 30 days following an MI. Factors demonstrating an association with higher odds of hsCRP ≥ 2 mg/L included lower hemoglobin, lower estimated glomerular filtration rate, and comorbidities such as heart failure, peripheral vascular disease, stroke, atrial fibrillation, diabetes mellitus, and rheumatoid diseases. A high risk of major adverse cardiovascular events and mortality was noted in patients with hsCRP ≥ 2 mg/L. Elevated hsCRP levels were present in most patients with MI. This biomarker not only enabled the detection of populations at high-inflammatory risk but also gained validation for having prognostic value in real-world healthcare settings.